Suppliers and packagers for THAM

THAM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hospira	THAM	tromethamine	SOLUTION;INJECTION	013025	NDA	Hospira, Inc.	0409-1593-04	6 BOTTLE, GLASS in 1 CASE (0409-1593-04) / 500 mL in 1 BOTTLE, GLASS (0409-1593-14)	2020-06-24

Suppliers and packagers for THAM

Last updated: June 8, 2026

THAM (Tris(hydroxymethyl)aminomethane) Suppliers for Pharmaceutical Use: Who Manufactures It, Under What Forms, and How to Source

THAM supply is fragmented across bulk-chemical producers and pharmaceutical-grade manufacturers. The sourcing picture is typically split by (1) bulk THAM and (2) finished parenteral or specialty formulations that use THAM as the buffer/alkalinizer (notably for metabolic acidosis). For procurement, the critical attributes are regulatory status (pharma-grade versus industrial), salt form (THAM base versus THAM-containing solutions), packaging, and geography.

The most actionable route to identify true “drug supply” competitors is to start from finished-drug labels and then trace THAM excipient supply channels back to chemical producers. Public supplier lists alone usually overstate the availability of pharmaceutical-grade THAM.

What suppliers make THAM (Tris(hydroxymethyl)aminomethane) bulk chemical for pharma?

THAM is primarily produced as a bulk specialty chemical, then used to manufacture pharmaceutical buffers and alkalinizing solutions. In pharma procurement, bulk THAM must meet pharmaceutical-grade specifications (or be qualified through supplier quality agreements and change-control).

Key supply modes used by THAM manufacturers

• Bulk THAM (active substance for formulation buffers)
• THAM-containing pharmaceutical solutions (finished liquids that may include additional buffers, electrolytes, or tonicity agents)
• Contract manufacturing for buffered parenteral solutions where THAM is the buffering agent

Where pharma-grade THAM bottlenecks typically occur

• Quality system readiness for drug substance supply (GMP/controlled manufacturing)
• Consistency of impurities (nitrogenous impurities and crystallization behavior)
• Stability for downstream formulation (pH range, CO2 absorption sensitivity, packaging headspace controls)

Which companies supply THAM for injectable or buffered pharmaceutical formulations?

In practice, the “suppliers” most relevant to a hospital or pharma buyer are the manufacturers of finished injectable solutions that contain THAM. Those finished products frequently source THAM bulk from chemical suppliers, but the label-level manufacturer is the contracting counterparty for drug product supply.

Common THAM use cases driving demand

• Treatment of metabolic acidosis via alkalinization (buffering)
• Buffering in specialized infusion products requiring tight pH control
• Use as part of formulations where THAM improves tolerability and pH management

Procurement implication

If the requirement is finished-drug supply, the contracting scope is the drug product manufacturer and their contract filling/packaging partners. If the requirement is formulation supply, the scope expands to THAM bulk suppliers plus GMP qualification of the bulk substance.

How do THAM supplier networks compare across US, EU, and ROW?

Supplier availability for THAM varies by region because pharmaceutical-grade manufacturing is more constrained than industrial chemical supply.

US and EU procurement patterns

• More frequent sourcing through GMP-validated chemical manufacturers for drug-formulation use
• Finished-dose supply may come from fewer specialized players with established parenteral capabilities
• Qualification documentation requirements (DMFs, CEPs, GMP certificates, batch analyses) shape shortlist decisions

ROW patterns

• Industrial-grade availability is often broader, but pharma-grade qualification is the gating factor
• Contract manufacturing and re-labeling networks are more common in some regions

What regulatory status should you require from THAM suppliers?

For drug formulation use, the regulatory question is whether THAM is supplied as drug substance under a suitable quality framework or whether it is supplied as part of a finished drug.

Drug substance expectations

• GMP manufacturing or equivalent quality system suitable for drug substance
• Impurity profiles and specification sheets aligned with intended dosage form
• Change control and traceability for critical manufacturing parameters

Finished product expectations

• Current GMP status for the drug product manufacturer
• Controlled packaging and stability data for the labeled product

Which THAM forms matter for sourcing: base vs solutions vs salts?

THAM’s practical sourcing decision usually comes down to the form you need for compounding or manufacturing.

Form-by-form sourcing implications

• THAM base: requires formulation validation for pH, solubility, and compatibility
• THAM-containing solutions: easier for pharmacy compounding environments but increases supply dependency on finished-product manufacturing
• Salt/solution variants: can change stability, viscosity, and compatibility with infusion sets and containers

How do you screen THAM suppliers for quality and supply continuity?

A typical high-risk screening process focuses on the supplier’s ability to sustain supply without changing critical parameters that affect downstream formulation performance.

Qualification checklist used in pharma sourcing

• Consistent batch quality and impurity control
• Documented change control procedures
• Ability to support validation and ongoing release testing needs
• Supply continuity track record, including resin/crystal supply and packaging supply reliability
• Regulatory documentation support for filings and audits

What generic entry risks affect THAM supply (and when do they matter)?

THAM itself is a buffering/alkalinizing substance rather than a blockbuster single-drug active ingredient in the same way as traditional small molecules. The practical “entry risk” for THAM is less about patent exclusivity and more about whether a qualified supplier exits the market or cannot meet parenteral-grade requirements.

Key risk scenario

• A narrow pool of pharma-grade THAM suppliers means shortages can occur even when industrial-grade supply exists.

What patent or exclusivity issues exist for THAM as an excipient/buffer?

THAM use as an excipient generally has fewer exclusivity constraints than branded drug actives. The bottleneck in practice is regulatory qualification and GMP supply, not patent protection.

Where IP can still appear

• Proprietary formulations of buffered parenteral solutions
• Process patents related to manufacturing a specific THAM-containing product
• Device or container compatibility IP (less common but present in some infusion products)

Key Takeaways

• THAM supply splits between bulk chemical producers and finished pharmaceutical solution manufacturers that use THAM as the buffer/alkalinizer.
• The highest procurement relevance is pharmaceutical-grade THAM qualification or finished drug product sourcing, not industrial chemical availability.
• Screening should prioritize consistent impurity control, GMP readiness, change control, documentation support, and supply continuity.
• Regional availability is constrained by drug-quality manufacturing capacity, not by general chemical production capacity.

FAQs

1) Can industrial THAM be used for pharmaceutical compounding?

Only if qualified under the intended pharmaceutical quality framework, with validated specifications, impurities control, and appropriate documentation for drug use.

2) Are THAM suppliers the same as suppliers for THAM-containing injectable products?

Not usually. Bulk THAM and finished injectable products are commonly sourced through different contracting tiers.

3) What is the most important spec to confirm with THAM suppliers?

Impurity profile and consistency aligned to your dosage form requirements, since downstream pH and stability can be sensitive to impurities.

4) How do I mitigate THAM supply disruption risk?

Qualify at least two sources where possible and require robust change control plus forecast-sharing mechanisms in supplier agreements.

5) Is THAM supply typically patent-protected?

THAM as a buffer has fewer direct exclusivity constraints than traditional drug actives; constraints typically come from GMP qualification and product/formulation IP rather than THAM itself.

References

1. None cited.